A Phase 4 interventional study of Ketorolac 0.4% and Lubricating Eye Drop in Inflammation, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-09-23.
Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,173 studies in Inflammation with a site in United States — 161 open to participants now, 214 under way, 6 of them phase 3. Inflammation · United States.
Among the 1,173 studies in Inflammation with a site in United States, this one is the 888th largest by enrollment of the 956 interventional ones that give a count, is one of 35 that started in 2008, is one of 73 in phase 4, and was the 214th registered.
3,541 studies on the registry are indexed under Inflammation; 646 are open to participants now.
Browse Inflammation studies →161 of the 1,173 studies in Inflammation with a site in United States are open now. Recruiting first, the newest first:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–85
University of Nebraska · Sites in United States
Ages 1 mo–3 yrs
Daniel Moriarity · Sites in United States
Ages 18+
University of Arkansas · Sites in United States
Ages 21–75 · Healthy volunteers
Vanderbilt University Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 461 Inflammation studies recruiting now, 174 (38%) set no upper age limit and 206 (45%) stop at 75 or younger; 56 take children under 18; 165 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,173 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 160 · Phase 2 241 · Phase 3 91 · Phase 4 73
First in 1978; this study’s year is marked. 35 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 50 across 2,582 interventional studies indexed under Inflammation.
Median enrollment 45 across the 956 interventional studies, 90 across the 214 observational. Of the 887 that completed or were terminated, 307 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
164 of 1,173 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
AbbVie has 2 studies filed under Inflammation — fewer than ten, so there is no comparison to draw.
79 of the studies in Inflammation with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05552053Phase 3Cedars-Sinai Medical CenterResources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women | 2026-12-31 |
| NCT05658575Phase 3Olatec Therapeutics, Inc.Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare | 2026-12-31 |
| NCT05699174Phase 3Major Extremity Trauma Research ConsortiumPO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation | 2027-09 |
| NCT03675724Mayo ClinicAlleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults | 2026-11 |
| NCT03430037Mayo ClinicAlleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women | 2026-11 |
Add all 79 to your calendar (.ics) → With an account.
Among the 1,173 studies in Inflammation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A pilot study to evaluate the extent of PGE2 inhibition (mean aqueous values) by Ketorolac 0.04% following peripheral iridotomy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Ketorolac 0.4%
Drug: Ketorolac 0.4%
Mineral Oil Emollient
Drug: Lubricating Eye Drop
One drop 4 times a day in the pre-operative eye beginning day 0 for 4 days
Also known as: Acular LS™
One drop 4 times a day in the operative eye beginning one day prior to the peripheral iridotomy and continuing until the day of IOL implantation
Also known as: Soothe® XP
Mean Prostaglandin E2 (PGE2) Aqueous Humor Levels
The mean level of PGE2 (a naturally occurring prostaglandin E2 in the eye that can cause inflammation and other complications) in the aqueous humor (the thin, watery fluid in the eye) 2 days following peripheral iridotomy (ocular surgery).
Time frame: Day 3
| Milestone | Ketorolac 0.4% | Soothe® XP |
|---|---|---|
| Started | 6 | 3 |
| Completed | 6 | 3 |
| Not completed | 0 | 0 |
The mean level of PGE2 (a naturally occurring prostaglandin E2 in the eye that can cause inflammation and other complications) in the aqueous humor (the thin, watery fluid in the eye) 2 days following peripheral iridotomy (ocular surgery).
| Picograms per milliliter (pg/ml) | Ketorolac 0.4% | Soothe® XP |
|---|---|---|
| Mean Prostaglandin E2 (PGE2) Aqueous Humor Levels | 1027.4 ± 429 | 1014.7 ± 196.8 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ketorolac 0.4% | — | 0/6 (0%) | 0/6 (0%) |
| Soothe® XP | — | 0/3 (0%) | 0/3 (0%) |
| Age Continuous(years) | Ketorolac 0.4% | Soothe® XP | Total |
|---|---|---|---|
| Mean | 30.2 ± 9.7 | 33.3 ± 2.5 | 31.75 ± 6.1 |
| Sex: Female, Male(Participants) | Ketorolac 0.4% | Soothe® XP | Total |
|---|---|---|---|
| Female | 5 | 1 | 6 |
| Male | 1 | 2 | 3 |
The record gives a start of Nov 2008, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2011, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ketorolac · Lubricant Eye Drops